Literature DB >> 2942236

DNA lesions in human neoplastic cells and cytotoxicity of 5-fluoropyrimidines.

U Lönn, S Lönn.   

Abstract

We have examined the induction of alkali-labile regions in DNA of human neoplastic cells treated with 5-fluorouracil and 5-fluorodeoxyuridine. 5-Fluorouracil induces DNA lesions by two mechanisms: incorporation of drug into DNA and a second mechanism not involving the incorporation. The second mechanism is seen in cells treated with aphidicolin, a specific inhibitor of DNA polymerase alpha, to stop the movement of the DNA replication forks. 5-Fluorodeoxyuridine is not incorporated into DNA of these cells; only the second mechanism of induction of alkali-labile DNA is detected. The second mechanism is in all probability due to inefficient DNA repair of normally occurring defects in purine and pyrimidine residues. Furthermore there is a correlation between increasing levels of alkali-labile regions in the DNA and cytotoxicity of the drugs. This may be one explanation for the cytocidal effects of 5-fluoropyrimidines.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2942236

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Systemic treatment of advanced colorectal cancer: tailoring therapy to the tumor.

Authors:  John M Carethers
Journal:  Therap Adv Gastroenterol       Date:  2008-07       Impact factor: 4.409

Review 2.  Chemotherapeutic implications in microsatellite unstable colorectal cancer.

Authors:  Won-Seok Jo; John M Carethers
Journal:  Cancer Biomark       Date:  2006       Impact factor: 4.388

3.  Mismatch repair proficiency and in vitro response to 5-fluorouracil.

Authors:  J M Carethers; D P Chauhan; D Fink; S Nebel; R S Bresalier; S B Howell; C R Boland
Journal:  Gastroenterology       Date:  1999-07       Impact factor: 22.682

4.  Effects of 5-fluorouracil on cytotoxicity and RNA metabolism in human colonic carcinoma cells.

Authors:  D A Greenhalgh; J H Parish
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

5.  In vivo comparative therapeutic study of optimal administration of 5-fluorouracil and cisplatin using a newly established HST-1 human squamous-carcinoma cell line.

Authors:  M Kuroki; S Nakano; K Mitsugi; I Ichinose; K Anzai; M Nakamura; S Nagafuchi; Y Niho
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 6.  Participation of DNA repair in the response to 5-fluorouracil.

Authors:  M D Wyatt; D M Wilson
Journal:  Cell Mol Life Sci       Date:  2009-03       Impact factor: 9.261

Review 7.  Clinical pharmacology of 5-fluorouracil.

Authors:  R B Diasio; B E Harris
Journal:  Clin Pharmacokinet       Date:  1989-04       Impact factor: 6.447

8.  Mechanisms of collateral sensitivity to fluorouracil of a cis-diamminedichloroplatinum(II)-resistant human non-small lung cancer cell line.

Authors:  Y Sugimoto; Y Ohe; K Nishio; T Ohmori; T Morikage; Y Fujiwara; N Saijo
Journal:  Br J Cancer       Date:  1992-06       Impact factor: 7.640

9.  Synergism between 5-fluorouracil and N-methylformamide in HT29 human colon cancer line.

Authors:  N Laudonio; G Zupi; E Erba; C Leonetti; M D'Incalci
Journal:  Br J Cancer       Date:  1990-03       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.